Janux Therapeutics (JANX) Expected to Announce Earnings on Tuesday

Janux Therapeutics (NASDAQ:JANXGet Free Report) is anticipated to issue its Q1 2025 quarterly earnings data before the market opens on Tuesday, May 6th. Analysts expect the company to announce earnings of ($0.42) per share and revenue of $0.59 million for the quarter.

Janux Therapeutics (NASDAQ:JANXGet Free Report) last released its quarterly earnings data on Thursday, February 27th. The company reported ($0.36) EPS for the quarter, topping the consensus estimate of ($0.49) by $0.13. Janux Therapeutics had a negative return on equity of 10.47% and a negative net margin of 463.91%. On average, analysts expect Janux Therapeutics to post $-1 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Janux Therapeutics Trading Up 2.6 %

NASDAQ JANX opened at $32.88 on Monday. The stock has a 50-day moving average of $29.80 and a 200-day moving average of $42.47. Janux Therapeutics has a 1-year low of $22.52 and a 1-year high of $71.71. The firm has a market cap of $1.95 billion, a PE ratio of -28.10 and a beta of 3.27.

Insider Buying and Selling

In other news, insider Andrew Hollman Meyer sold 3,333 shares of the business’s stock in a transaction on Thursday, May 1st. The shares were sold at an average price of $32.03, for a total transaction of $106,755.99. Following the sale, the insider now owns 82,139 shares in the company, valued at approximately $2,630,912.17. The trade was a 3.90 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Ra Capital Management, L.P. bought 110,206 shares of Janux Therapeutics stock in a transaction dated Friday, March 7th. The stock was acquired at an average cost of $31.02 per share, for a total transaction of $3,418,590.12. Following the completion of the transaction, the director now directly owns 10,141,287 shares in the company, valued at approximately $314,582,722.74. This trade represents a 1.10 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders sold a total of 10,001 shares of company stock valued at $313,964 over the last three months. Corporate insiders own 29.40% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on the company. HC Wainwright reissued a “buy” rating and set a $70.00 price objective on shares of Janux Therapeutics in a research note on Monday, March 3rd. Scotiabank dropped their price target on shares of Janux Therapeutics from $62.00 to $41.00 and set a “sector perform” rating for the company in a research report on Friday, February 28th. William Blair reissued an “outperform” rating on shares of Janux Therapeutics in a report on Friday, January 10th. Finally, Wedbush reaffirmed an “outperform” rating and set a $76.00 price objective (up from $75.00) on shares of Janux Therapeutics in a research note on Friday, February 28th. One analyst has rated the stock with a hold rating, eight have given a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat, the stock has an average rating of “Buy” and a consensus price target of $95.25.

Check Out Our Latest Stock Report on Janux Therapeutics

About Janux Therapeutics

(Get Free Report)

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.

Featured Articles

Earnings History for Janux Therapeutics (NASDAQ:JANX)

Receive News & Ratings for Janux Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Janux Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.